Ken B. Waites

Ken B. Waites

Auto-generated profile, based on publicly available information

Ken B. Waites

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
KWKen B. Waites
Ken B. Waites
LXLi Xiao
Li Xiao
YLYang Liu
Yang Liu
MBMitchell F. Balish
Mitchell F. Balish
TAT. Prescott Atkinson
T. Prescott Atkinson
SUMMARY: Mycoplasma pneumoniaeis an important cause of respiratory tract infections in children as well as adults that can range in severity from mild to life-threatening. Over the past several years there has been much new information published concerning infections caused by this organism. New molecular-based tests forM. pneumoniaedetection are now commercially available in the United States, and advances in molecular typing systems have enhanced understanding of the epidemiology of infections. More strains have had their entire genome sequences published, providing additional insights into pathogenic mechanisms. Clinically significant acquired macrolide resistance has emerged worldwide and is now complicating treatment.In vitrosusceptibility testing methods have been standardized, and several new drugs that may be effective against this organism are undergoing development. This review focuses on the many new developments that have occurred over the past several years that enhance our understanding of this microbe, which is among the smallest bacterial pathogens but one of great clinical importance.

1 November 2019 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
KWK B Waites
K B Waites
ARA Ratliff
A Ratliff
DCD M Crabb
D M Crabb
LXL Xiao
L Xiao
XQX Qin
X Qin
TAT P Atkinson
T P Atkinson
There are sparse data to indicate the extent that macrolide-resistant Mycoplasma pneumoniae (MRMp) occurs in the United States or its clinical significance. Between 2015 and 2018, hospitals in 8 states collected and stored respiratory specimens that tested positive for Mp and sent them to the University of Alabama at Birmingham where real-time PCR was performed for detection of 23S rRNA mutations known to confer macrolide resistance. MRMp was detected in 27 of 360 specimens (7.5%). MRMp prevalence was significantly higher in the South and East (18.3%) than in the West (2.1%). A2063G was the predominant 23S rRNA mutation detected. MICs for macrolide-susceptible M. pneumoniae (MSMp) were ≤ 0.008 μg/ml, whereas MICs for MRMp were 16 – 32 μg/ml. Patients with MRMp infection were more likely to have a history of immunodeficiency or malignancy. Otherwise, there were no other significant differences in clinical features of MRMp versus MSMp, nor were there any differences in radiographic findings, hospitalization rates, viral co-infections, mean duration for antimicrobial treatment, or clinical outcomes. There was no significant change in MRMp incidence over time or according to age, sex, race/ethnicity, or status as inpatient or outpatient. Patients with MRMp were more likely to have received a macrolide prior to presentation and more likely to have been changed to a fluoroquinolone after presentation. This is the first national surveillance program for Mp in the United States. Additional surveillance is needed to assess clinical significance and to monitor changes in MRMp prevalence.

1 February 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KWKen B. Waites
Ken B. Waites
DCDonna M. Crabb
Donna M. Crabb
LDLynn B. Duffy
Lynn B. Duffy
JJJørgen Skov Jensen
Jørgen Skov Jensen
YLYang Liu
Yang Liu
SPSusanne Paukner
Susanne Paukner
Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC 90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

22 September 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
LXLi Xiao
Li Xiao
ARA. E. Ratliff
A. E. Ratliff
DCD. M. Crabb
D. M. Crabb
EME. Mixon
E. Mixon
XQX. Qin
X. Qin
KWK. B. Waites
K. B. Waites
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. There are limited data in the United States on the molecular epidemiological characteristics of M. pneumoniae. We collected 446 M. pneumoniae-positive specimens from 9 states between August 2012 and October 2018. Culture, antimicrobial susceptibility testing, P1 subtyping, and multilocus VNTR (variable-number tandem repeats) analysis (MLVA) were performed to characterize the isolates. Macrolide-resistant M. pneumoniae (MRMp) was detected in 37 (8.3%) specimens. P1 subtype 2 (P1-2) was the predominant P1 subtype (59.8%). P1 subtype distribution did not change significantly chronologically or geographically. The macrolide resistance rate in P1 subtype 1 (P1-1) samples was significantly higher than that in P1-2 (12.9% versus 5.5%). Six P1-2 variants were identified, including two novel types, and variant 2c was predominant (64.6%). P1-2 variants were distributed significantly differently among geographic regions. Classical P1-2 was more frequent in lower respiratory tract specimens and had longer p1 trinucleotide repeats. Classical P1-2 was most common in MRMp (35.7%), while variant 2c was most common in macrolide-susceptible M. pneumoniae (67.5%). Fifteen MLVA types were identified; 3-5-6-2 (41.7%), 4-5-7-2 (35.3%), and 3-6-6-2 (16.6%) were the major types, and four MLVA clusters were delineated. The distribution of MLVA types varied significantly over time and geographic location. The predominant MLVA type switched from 4-5-7-2 to 3-5-6-2 in 2015. MLVA type was associated with P1 subtypes and P1-2 variant types but not with macrolide resistance. To investigate the M. pneumoniae genotype shift and its impact on clinical presentations, additional surveillance programs targeting more diverse populations and prolonged sampling times are required.

4 January 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
KWKen B. Waites
Ken B. Waites
DCDonna M. Crabb
Donna M. Crabb
ARAmy E. Ratliff
Amy E. Ratliff
WGWilliam M. Geisler
William M. Geisler
TAT. Prescott Atkinson
T. Prescott Atkinson
LXLi Xiao
Li Xiao
Mycoplasma genitalium is an important sexually transmitted pathogen affecting both men and women. Its extremely slow growth in vitro and very demanding culture requirements necessitate the use of molecular-based diagnostic tests for its detection in clinical specimens.

1 December 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KWKen B. Waites
Ken B. Waites
DCDonna M. Crabb
Donna M. Crabb
YLYang Liu
Yang Liu
LDLynn B. Duffy
Lynn B. Duffy
In vitro activities of omadacycline, a new aminomethylcycline, were determined for Mycoplasma and Ureaplasma spp. and compared with those of azithromycin, clindamycin, moxifloxacin, tetracycline, and doxycycline. All omadacycline MICs were <2 μg/ml. MIC 90 s were 0.063 μg/ml for Mycoplasma hominis , 0.25 μg/ml for Mycoplasma pneumoniae , and 2 μg/ml for Ureaplasma spp. Omadacycline had the lowest MIC 90 among all drugs tested against M. hominis . Omadacycline activity was not affected by macrolide, tetracycline, or fluoroquinolone resistance.